Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
681-700 of 1,738 trials

Advanced Solid Tumors: ANV600 and Pembrolizumab Study

We are testing a new treatment, ANV600, alone and with pembrolizumab for people with advanced solid tumors. The goal is to evaluate safety and how well it may help fight cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Peripheral T Cell Lymphoma: LIS1 Antibody Study

We are testing a new antibody treatment for patients with relapsed or refractory peripheral T cell lymphoma. The study aims to evaluate its safety and effectiveness in fighting this type of cancer.

Peripheral T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

High-Risk Neuroblastoma: Dinutuximab Beta with Chemotherapy

We are studying the safety and effectiveness of combining dinutuximab beta with two chemotherapy regimens for children with newly diagnosed high-risk neuroblastoma. This research aims to improve treatment options and outcomes for these young patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Alzheimer's Disease: RO7126209 IV Treatment Study

We are investigating a new intravenous medication for individuals with mild to moderate Alzheimer's disease. The study aims to assess its safety and how it affects the brain over multiple doses.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Ponatinib for Pediatric Leukemias and Solid Tumors

We are studying the safety and effectiveness of ponatinib in children with recurrent or hard-to-treat leukemias and solid tumors. This trial aims to help those who have not responded to other therapies.

Acute Myeloid LeukaemiaChronic Myeloid Leukaemia1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Narsoplimab for Children with High-Risk Stem Cell Transplant Complications

We are studying whether narsoplimab can improve survival and safety in children with thrombotic microangiopathy after stem cell transplants. This trial will help us understand how well this treatment works and its effects on young patients.

Thrombotic Microangiopathy1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

Burning Mouth Syndrome: Clonazepam Treatment Study

We are exploring how a topical treatment with clonazepam affects pain and other symptoms in people with burning mouth syndrome. The study will also look at patient preferences and experiences with the treatment over time.

Burning Mouth Syndrome6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyPsychiatry

Pulmonary Aspergillosis: MIRAGE Imaging Study

We are testing a new imaging method using a radioactive substance to see if it helps visualize lung infections caused by Aspergillus. This study aims to improve diagnosis and understanding of this condition.

Pulmonary AspergillosisEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy Type 1

We are studying a new treatment for adults with Facioscapulohumeral Muscular Dystrophy Type 1 to see how safe it is and how it works in the body. This trial will help us understand its effects with different doses.

Facioscapulohumeral Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Metastatic Colorectal Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with metastatic colorectal cancer who have not responded to standard care. The study aims to see if this new drug can improve survival and response rates compared to existing treatments.

Metastatic Colorectal CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

COVID-19 Treatment: Nirmatrelvir/Ritonavir for Children

We are studying a new oral medication for children with COVID-19 who are at risk of severe illness. The trial will evaluate its safety, how well it works, and how it is tolerated in young patients.

COVID-19Efficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Ulcerative Colitis in Kids: Vedolizumab vs. Infliximab

We are comparing the safety and effectiveness of a new treatment, vedolizumab, with the standard treatment, infliximab, for children aged 6-17 with ulcerative colitis. This study aims to find out which treatment works better for young patients.

Ulcerative Colitis3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Ibrutinib for Autoimmune Hemolytic Anemia in CLL Patients

We are studying whether ibrutinib can effectively treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia or similar conditions. The trial will also look at the safety and quality of life during treatment.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Non-Small Cell Lung Cancer: Cemiplimab with Chemotherapy

We are studying whether adding new cancer treatments to cemiplimab and chemotherapy helps patients with operable non-small cell lung cancer. This trial aims to evaluate the effectiveness and safety of these combined treatments.

Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Early Alzheimer's Disease: Sabirnetug Infusions

We are studying whether intravenous sabirnetug can slow cognitive decline in people with early Alzheimer's disease compared to a placebo. This trial aims to find new ways to help manage symptoms and improve quality of life.

Early Alzheimer's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Childhood Leukemia: Inotuzumab Ozogamicin vs. ALLR3

We are studying whether Inotuzumab Ozogamicin works better than standard treatment for children with high-risk first relapse B-cell leukemia. The trial focuses on safety and long-term effectiveness in young patients.

Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

De-escalating Treatment for HER2-Positive Metastatic Breast Cancer

We are studying whether reducing treatment is safe for patients with undetectable cancer levels after long-term therapy. This trial aims to assess the impact on survival and quality of life.

HER2-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Oligometastatic Colorectal Cancer: OPTIMISE Study

We are exploring whether a blood test can help decide the best treatment for patients with oligometastatic colorectal cancer. The study also looks at how this approach affects quality of life and treatment costs.

Colorectal Cancer with MetastasisEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: BI-1206 with Pembrolizumab

We are studying a new treatment combining BI-1206 and pembrolizumab for patients with advanced solid tumors. This trial aims to find a safe dose and understand how well this combination works for those with specific types of cancer.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Advanced Cancers: BI-1808 Monoclonal Antibody

We are studying a new treatment called BI-1808 for people with advanced cancers, both alone and with pembrolizumab. The goal is to assess its safety and how well it is tolerated by patients.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology